Potent inhibition of human immunodeficiency virus type 1 replication by conditionally replicating human immunodeficiency virus-based lentiviral vectors expressing envelope antisense mRNA.

We describe an HIV-based lentiviral vector that expresses a 1-kb antisense mRNA directed against the HIV-1 mRNAs containing env sequences. The expression of antisense env mRNAs (envAS) does not inhibit the synthesis of p24 expressed from the HIV-1 helper plasmid used to package the vector, as this helper has a deletion in the env gene. This allows the production of high-titer VSV-G pseudotyped lentiviral particles. In challenge experiments using unselected populations of SupT1 cells transduced with this vector, a complete inhibition of HIV-1 replication was observed for long periods of in vitro culture, even at high HIV-1 infectious doses. The potent inhibition of HIV-1 replication by this vector correlated with a low occurrence of mobilization of the vector to previously untransduced cells. The infectivity of the wild-type HIV-1 that escapes inhibition was highly inhibited, suggesting that the vector is providing HIV-1 inhibition of replication not only due to its antisense effect but also by competing for encapsidation and mobilization to noninfected cells.

[1]  J. Rossi,et al.  Delivery of novel macromolecular drugs against HIV-1 , 2001, Expert opinion on biological therapy.

[2]  R. Morgan,et al.  Modified human immunodeficiency virus-based lentiviral vectors display decreased sensitivity to trans-dominant Rev. , 2000, Human gene therapy.

[3]  Qi-Xiang Li,et al.  An Inducible Human Immunodeficiency Virus Type 1 (HIV-1) Vector Which Effectively Suppresses HIV-1 Replication , 1999, Journal of Virology.

[4]  L. Naldini,et al.  Interaction of Human Immunodeficiency Virus-Derived Vectors with Wild-Type Virus in Transduced Cells , 1999, Journal of Virology.

[5]  D. Trono,et al.  A Third-Generation Lentivirus Vector with a Conditional Packaging System , 1998, Journal of Virology.

[6]  E. Poeschla,et al.  A controlled, Phase 1 clinical trial to evaluate the safety and effects in HIV-1 infected humans of autologous lymphocytes transduced with a ribozyme that cleaves HIV-1 RNA. , 1998, Human gene therapy.

[7]  F. Wong-Staal,et al.  Anti-HIV effects of HIV vectors. , 1998, Virology.

[8]  H. Kaneshima,et al.  Comparative Analyses of Intracellularly Expressed Antisense RNAs as Inhibitors of Human Immunodeficiency Virus Type 1 Replication , 1998, Journal of Virology.

[9]  G. Nabel,et al.  Enhanced T cell engraftment after retroviral delivery of an antiviral gene in HIV-infected individuals. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[10]  J. Clements,et al.  Reduction in SIV replication in rhesus macaques infused with autologous lymphocytes engineered with antiviral genes , 1998, Nature Medicine.

[11]  A. Gervaix,et al.  Gene therapy targeting cord blood-derived CD34+ cells from HIV-exposed infants: preclinical studies , 1998, Gene Therapy.

[12]  C. Vaquero,et al.  Expression of naturally occurring antisense RNA inhibits human immunodeficiency virus type 1 heterologous strain replication. , 1997, The Journal of general virology.

[13]  G. Nuovo,et al.  Stable human immunodeficiency virus type 1 (HIV-1) resistance in transformed CD4+ monocytic cells treated with multitargeting HIV-1 antisense sequences incorporated into U1 snRNA , 1997, Journal of virology.

[14]  S. Karlsson,et al.  Transduction of nondividing cells using pseudotyped defective high-titer HIV type 1 particles. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[15]  F. Gage,et al.  Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[16]  M. Heřmánková,et al.  A conditionally replicating HIV-1 vector interferes with wild-type HIV-1 replication and spread. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[17]  R. Morgan,et al.  Gene therapy for AIDS using retroviral mediated gene transfer to deliver HIV-1 antisense TAR and transdominant Rev protein genes to syngeneic lymphocytes in HIV-1 infected identical twins. , 1996, Human gene therapy.

[18]  F. Gage,et al.  In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector , 1996, Science.

[19]  G. Palù,et al.  A new antisense tRNA construct for the genetic treatment of human immunodeficiency virus type 1 infection , 1996, Journal of virology.

[20]  M. Daucher,et al.  Analysis of trans-dominant mutants of the HIV type 1 Rev protein for their ability to inhibit Rev function, HIV type 1 replication, and their use as anti-HIV gene therapeutics. , 1995, AIDS research and human retroviruses.

[21]  R. Morgan,et al.  Inhibition of clinical human immunodeficiency virus (HIV) type 1 isolates in primary CD4+ T lymphocytes by retroviral vectors expressing anti-HIV genes , 1995, Journal of virology.

[22]  R. Morgan,et al.  Inhibition of human immunodeficiency virus type-1 by retroviral vectors expressing antisense-TAR. , 1994, Human gene therapy.

[23]  H. Buc,et al.  HIV-1 reverse transcription. A termination step at the center of the genome. , 1994, Journal of molecular biology.

[24]  E. Poeschla,et al.  Transfer of an anti-HIV-1 ribozyme gene into primary human lymphocytes. , 1994, Human gene therapy.

[25]  J. Garcia,et al.  Construction and properties of retrovirus packaging cells based on gibbon ape leukemia virus , 1991, Journal of virology.

[26]  Miller Ad,et al.  Improved Retroviral Vectors for Gene Transfer and Expression , 1989 .

[27]  H. Gendelman,et al.  Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone , 1986, Journal of virology.

[28]  A. Riggs,et al.  Sequence of the promoter region of the gene for human X-linked 3-phosphoglycerate kinase. , 1984, Gene.

[29]  R. Morgan,et al.  Inhibition of human immunodeficiency virus type 1 by Tat/Rev-regulated expression of cytosine deaminase, interferon alpha2, or diphtheria toxin compared with inhibition by transdominant Rev. , 1999, Human gene therapy.

[30]  S. Rosenberg,et al.  Interleukin-2-transduced lymphocytes grow in an autocrine fashion and remain responsive to antigen. , 1995, Blood.

[31]  R. Joshi,et al.  Inhibition of HIV-1 multiplication in a human CD4+ lymphocytic cell line expressing antisense and sense RNA molecules containing HIV-1 packaging signal and Rev response element(s). , 1994, Antisense research and development.